Bicara Therapeutics Inc. (BCAX) shareholders
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.02−0.09 (-0.89%)
Close on Nov 13, 2026Market cap $663.05MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
70M of 66M shares
Institutional holders
171
39 new, 11 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
1 buys · 57 sales
Net sold $5.11M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (11.50%), Rajeev Shah (11.50%) and 1 more | 7,279,739 | 11.50% | 13D (active) amendment | Feb 26, 2026 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (8.30%) | 5,425,000 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (8.90%), Invus Public Equities Advisors, LLC (8.90%) and 2 more | 5,216,969 | 9.60% | 13G (passive) amendment | Jun 30, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (6.21%), David Kroin (6.21%) | 4,062,500 | 6.21% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 3,536,271 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Janus Henderson Group PLC | 3,339,218 | 5.10% | 13G (passive) | Mar 31, 2026 |
| James G. Coulter Joint filing with Tpg Gp A, LLC (5.50%), David Bonderman (5.50%) and 1 more | 3,010,425 | 5.50% | 13D (active) | Sep 16, 2024 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (5.10%) | 2,768,975 | 5.10% | 13G (passive) | Mar 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (5.10%) | 2,756,217 | 5.10% | 13G (passive) | Jul 10, 2025 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (5.02%), David Kroin (5.02%) | 2,750,000 | 5.02% | 13G (passive) | Feb 5, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BCAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 7,255,993 | 10.97% | $215.43M | – | 1.87% |
| T. Rowe Price Investment Management, Inc. | 6,338,487 | 9.58% | $188.19M | −267,293 | 0.12% |
| Siren, L.L.C. | 5,602,970 | 8.47% | $166.35M | −200,000 | 3.37% |
| Vestal Point Capital, LP | 5,250,000 | 7.93% | $155.87M | −175,000 | 3.64% |
| Deep Track Capital, LP | 4,100,000 | 6.20% | $121.73M | +37,500 | 1.77% |
| BlackRock, Inc. | 3,848,090 | 5.82% | $114.25M | +1,004,383 | 0.00% |
| Jupiter Topco LLC | 3,171,015 | 4.79% | $93.96M | New | 0.04% |
| Red Tree Management, LLC | 3,163,517 | 4.78% | $93.92M | −6,992 | 63.77% |
| Tpg Gp A, LLC | 3,010,425 | 4.55% | $89.38M | – | 1.79% |
| Vanguard Capital Management LLC | 2,216,639 | 3.35% | $65.81M | +442,419 | 0.00% |
| State Street Corp | 2,048,920 | 3.10% | $60.83M | +629,532 | 0.00% |
| Franklin Resources Inc | 1,951,892 | 2.95% | $57.95M | +330,249 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,904,248 | 2.88% | $56.54M | +528,050 | 0.01% |
| FMR LLC | 1,893,070 | 2.86% | $56.21M | −207,859 | 0.00% |
| Omega Fund Management, LLC | 1,822,150 | 2.75% | $54.10M | −570,000 | 29.14% |
| Geode Capital Management, LLC | 1,162,635 | 1.76% | $34.53M | +331,729 | 0.00% |
| JPMorgan Chase & Co | 1,015,965 | 1.54% | $29.81M | +838,557 | 0.00% |
| Jones Hill Capital LP | 892,621 | 1.35% | $26.50M | −367,515 | 5.63% |
| Acorn Capital Advisors, LLC | 643,381 | 0.97% | $19.10M | −1 | 5.21% |
| Aisling Capital Management LP | 568,919 | 0.86% | $16.89M | – | 3.58% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 171 | 70M | 100.0% | 39 / 67 | 39 / 11 | 11M | 6M |
| Q1 2026 | 145 | 69M | 100.0% | 29 / 57 | 40 / 21 | 17M | 3M |
| Q4 2025 | 140 | 57M | 86.5% | 44 / 45 | 35 / 17 | 13M | 6M |
| Q3 2025 | 114 | 50M | 75.9% | 25 / 42 | 25 / 17 | 3M | 4M |
| Q2 2025 | 106 | 51M | 77.3% | 33 / 43 | 16 / 19 | 13M | 10M |
| Q1 2025 | 93 | 49M | 73.5% | 28 / 26 | 19 / 18 | 7M | 6M |
| Q4 2024 | 84 | 47M | 70.6% | 39 / 23 | 7 / 24 | 14M | 3M |
| Q3 2024 | 69 | 36M | 55.0% | 69 / 0 | 0 / 0 | 36M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
179 funds held BCAX in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BCAX | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2,179,330 | 3.29% | $64.70M | 0.70% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,676,653 | 2.53% | $49.78M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 1,170,492 | 1.77% | $34.75M | 0.69% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,149,801 | 1.74% | $34.14M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,096,543 | 1.66% | $32.56M | 0.30% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 944,900 | 1.43% | $20.55M | 0.39% | May 31, 2026 |
| Franklin Small Cap Growth Fund | 623,692 | 0.94% | $16.90M | 0.68% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 612,100 | 0.93% | $18.17M | 0.19% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 604,729 | 0.91% | $17.95M | 0.17% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 591,014 | 0.89% | $17.55M | 0.15% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 491,079 | 0.74% | $14.58M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 483,715 | 0.73% | $13.11M | 0.04% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 474,899 | 0.72% | $12.87M | 1.11% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 356,291 | 0.54% | $10.58M | 0.07% | Jun 30, 2026 |
| iShares Biotechnology ETF | 264,967 | 0.40% | $7.87M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ryan Cohlhepp | President, COO & Interim CEO, Director | 199,141 | 0.30% | Sep 10, 2026 |
| Claire Mazumdar | Chief Executive Officer, Director | 372,152 | 0.56% | Aug 12, 2026 |
| Jennifer Larson | Chief Financial Officer | – | – | Aug 14, 2026 |
| Ivan Hyep | Chief Financial Officer | 129,855 | 0.20% | Aug 12, 2026 |
| William Schelman | Chief Medical Officer | – | – | May 12, 2026 |
| David Raben | Chief Medical Officer | 60,786 | 0.09% | Apr 28, 2026 |
| Lara Meisner | Chief Legal Officer | 0 | – | Feb 4, 2026 |
| Christy J. Oliger | Director | – | – | Jul 29, 2026 |
| Jeremy Bender | Director | – | – | Jul 29, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 10, 2026 |
| Kate Haviland | Director | 7,437 | 0.01% | Jun 10, 2026 |
| Michael Powell | Director | – | – | Jun 10, 2026 |
| Christopher Bowden | Director | – | – | Jun 10, 2026 |
| Jake Simson | Director | – | – | Jun 10, 2026 |
| Scott M. Robertson | Director | – | – | Jun 10, 2026 |
| Kiran Mazumdar-Shaw | Director | 6,297,854 | 9.52% | Jun 10, 2026 |
| Capital Healthcare Fund LP RA | Director | – | – | Jun 10, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 4,603,418 | 6.96% | Jun 10, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | – | Jun 10, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | 2,622,898 | 3.96% | Jun 10, 2026 |
| Nils Lonberg | Director | 29,991 | 0.05% | Jun 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ryan Cohlhepp President, COO & Interim CEO, Director | Sep 8, 2026 | Option exercise | +17,500 | $3.79 | $66.33K | 199,141 |
| Ryan Cohlhepp President, COO & Interim CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −14,058 | $22.77 | $320.10K | 185,083 |
| Ryan Cohlhepp President, COO & Interim CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −3,442 | $23.43 | $80.65K | 181,641 |
| Ryan Cohlhepp President and COO, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −18,750 | $27.98 | $524.63K | 181,641 |
| Ryan Cohlhepp President and COO, Director | Aug 10, 2026 | Option exercise | +18,750 | $3.79 | $71.06K | 200,391 |
| Ivan Hyep Chief Financial Officer | Aug 10, 2026 | Sale(10b5-1 plan) | −12,500 | $27.97 | $349.63K | 129,855 |
| Ivan Hyep Chief Financial Officer | Aug 10, 2026 | Option exercise | +12,500 | $3.79 | $47.38K | 142,355 |
| Claire Mazumdar Chief Executive Officer, Director | Aug 10, 2026 | Option exercise | +10,000 | $3.79 | $37.90K | 372,152 |
| Claire Mazumdar Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −10,000 | $27.98 | $279.80K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −28 | $29.68 | $831 | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −9,972 | $28.42 | $283.40K | 362,180 |
| Claire Mazumdar Chief Executive Officer, Director | Jul 10, 2026 | Option exercise | +10,000 | $3.79 | $37.90K | 372,152 |
| Ryan Cohlhepp President and COO, Director | Jul 9, 2026 | Sale(10b5-1 plan) | −536 | $29.00 | $15.54K | 181,641 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −4,413 | $29.82 | $131.60K | 130,685 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −22,757 | $28.60 | $650.85K | 135,098 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Option exercise | +12,500 | $3.79 | $47.38K | 157,855 |
| Ivan Hyep Chief Financial Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −830 | $30.31 | $25.16K | 129,855 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −4,306 | $29.80 | $128.32K | 183,252 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −1,075 | $30.35 | $32.63K | 182,177 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −22,833 | $28.76 | $656.68K | 187,558 |
| Ryan Cohlhepp President and COO, Director | Jul 8, 2026 | Option exercise | +18,750 | $3.79 | $71.06K | 210,391 |
| Ivan Hyep Chief Financial Officer | May 21, 2026 | Sale(10b5-1 plan) | −9,200 | $20.42 | $187.86K | 145,355 |
| Ivan Hyep Chief Financial Officer | May 21, 2026 | Option exercise | +9,200 | $3.79 | $34.87K | 154,555 |
| Claire Mazumdar Chief Executive Officer, Director | May 18, 2026 | Sale(10b5-1 plan) | −2,978 | $20.35 | $60.60K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | May 18, 2026 | Option exercise | +15,000 | $3.79 | $56.85K | 377,152 |
| Claire Mazumdar Chief Executive Officer, Director | May 18, 2026 | Sale(10b5-1 plan) | −12,022 | $19.96 | $239.96K | 365,130 |
| Ryan Cohlhepp President and COO, Director | May 15, 2026 | Sale(10b5-1 plan) | −4,500 | $20.29 | $91.31K | 191,641 |
| Ryan Cohlhepp President and COO, Director | May 15, 2026 | Sale(10b5-1 plan) | −8,000 | $20.29 | $162.32K | 196,141 |
| Ryan Cohlhepp President and COO, Director | May 15, 2026 | Option exercise | +8,000 | $3.79 | $30.32K | 204,141 |
| David Raben Chief Medical Officer | Apr 27, 2026 | Option exercise | +5,500 | $3.79 | $20.85K | 60,786 |
| David Raben Chief Medical Officer | Apr 27, 2026 | Sale(10b5-1 plan) | −5,500 | $22.88 | $125.84K | 55,286 |
| Ivan Hyep Chief Financial Officer | Apr 21, 2026 | Option exercise | +9,200 | $3.79 | $34.87K | 154,555 |
| Ivan Hyep Chief Financial Officer | Apr 21, 2026 | Sale(10b5-1 plan) | −9,200 | $23.00 | $211.60K | 145,355 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 20, 2026 | Option exercise | +15,000 | $3.79 | $56.85K | 377,152 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 20, 2026 | Sale(10b5-1 plan) | −15,000 | $23.61 | $354.15K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 16, 2026 | Option exercise | +7,080 | $5.45 | $38.59K | 362,152 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 16, 2026 | Option exercise | +7,454 | $3.79 | $28.25K | 355,072 |
| Claire Mazumdar Chief Executive Officer, Director | Apr 16, 2026 | Option exercise | +8,226 | $4.44 | $36.52K | 347,618 |
| Ryan Cohlhepp President and COO, Director | Apr 15, 2026 | Option exercise | +8,000 | $3.79 | $30.32K | 208,641 |
| Ryan Cohlhepp President and COO, Director | Apr 15, 2026 | Sale(10b5-1 plan) | −8,000 | $23.01 | $184.08K | 200,641 |
| Ryan Cohlhepp President and COO, Director | Apr 15, 2026 | Sale(10b5-1 plan) | −4,500 | $23.01 | $103.55K | 196,141 |
| David Raben Chief Medical Officer | Mar 25, 2026 | Option exercise | +5,500 | $3.79 | $20.85K | 60,786 |
| David Raben Chief Medical Officer | Mar 25, 2026 | Sale(10b5-1 plan) | −5,500 | $18.95 | $104.23K | 55,286 |
| Ivan Hyep Chief Financial Officer | Mar 23, 2026 | Sale(10b5-1 plan) | −9,200 | $18.52 | $170.38K | 145,355 |
| Ivan Hyep Chief Financial Officer | Mar 23, 2026 | Option exercise | +9,200 | $3.79 | $34.87K | 154,555 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 20, 2026 | Option exercise | +1,596 | $3.79 | $6.05K | 340,988 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 20, 2026 | Sale(10b5-1 plan) | −1,596 | $18.95 | $30.24K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 19, 2026 | Option exercise | +6,905 | $3.79 | $26.17K | 346,297 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 19, 2026 | Sale(10b5-1 plan) | −6,905 | $18.78 | $129.68K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 18, 2026 | Option exercise | +6,499 | $3.79 | $24.63K | 345,891 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 18, 2026 | Sale(10b5-1 plan) | −6,499 | $18.84 | $122.44K | 339,392 |
| Ryan Cohlhepp President and COO, Director | Mar 16, 2026 | Option exercise | +8,000 | $3.79 | $30.32K | 213,141 |
| Ryan Cohlhepp President and COO, Director | Mar 16, 2026 | Sale(10b5-1 plan) | −4,500 | $19.66 | $88.47K | 200,641 |
| Ryan Cohlhepp President and COO, Director | Mar 16, 2026 | Sale(10b5-1 plan) | −8,000 | $19.66 | $157.28K | 205,141 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 9, 2026 | Option exercise | +36,766 | $3.79 | $139.34K | 376,158 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −36,766 | $19.17 | $704.80K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 6, 2026 | Option exercise | +3,817 | $3.79 | $14.47K | 343,209 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 6, 2026 | Sale(10b5-1 plan) | −3,817 | $18.75 | $71.57K | 339,392 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 5, 2026 | Option exercise | +1,786 | $3.79 | $6.77K | 341,178 |
| Claire Mazumdar Chief Executive Officer, Director | Mar 5, 2026 | Sale(10b5-1 plan) | −1,786 | $18.74 | $33.47K | 339,392 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
20.06%
10M shares short
Days to cover
3.8
At 3M shares a day
Change since last report
-4.2%
From 10M shares
Short volume, 20 days
33.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bicara Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,564 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Raben Officer | Oct 21, 2026 | 24,777 | $449.03K | Oct 21, 2026 | Stock Option Exercise |
| Ryan Cohlhepp Officer, Director | Sep 8, 2026 | 17,500 | $396.20K | Sep 8, 2026 | Exercise of Stock Option |
| Ivan Hyep Officer | Sep 8, 2026 | 12,500 | $283.00K | Sep 8, 2026 | Exercise of stock options |
| Ivan Hyep Officer | Aug 10, 2026 | 12,500 | $347.88K | Aug 10, 2026 | Exercise of stock options |
| Ryan Cohlhepp Officer, Director | Aug 10, 2026 | 18,750 | $521.81K | Aug 10, 2026 | Exercise of Stock Option |
| Claire Mazumdar Officer, Director | Aug 10, 2026 | 10,000 | $278.30K | Aug 10, 2026 | Exercise of stock options |
| Claire Mazumdar Officer, Director | Jul 10, 2026 | 10,000 | $296.80K | Jul 10, 2026 | Exercise of stock options |
| David Raben Officer | Jul 8, 2026 | 50,000 | $1.43M | Jul 8, 2026 | Stock Option Exercise |
| Ryan Cohlhepp Officer, Director | Jul 8, 2026 | 28,750 | $869.69K | Jul 8, 2026 | Exercise of Stock Option |
| Ivan Hyep Officer | Jul 8, 2026 | 28,000 | $847.00K | Jul 8, 2026 | Exercise of stock options |
| Lara Meisner Officer | Jul 7, 2026 | 1,000 | $29.77K | Jul 7, 2026 | Stock Option Exercise |
| David Raben Officer | Jun 25, 2026 | 50,000 | $1.32M | Jun 25, 2026 | Stock Option Exercise |
| Lara Meisner Former Chief Legal Officer | Jun 1, 2026 | 71,390 | $1.47M | Jun 1, 2026 | Exercise of Stock Options |
| David Raben Officer | May 26, 2026 | 5,500 | $120.01K | May 26, 2026 | Exercise of Stock Options |
| Ivan Hyep Officer | May 21, 2026 | 9,200 | $187.88K | May 21, 2026 | Exercise of stock options |
See a number that looks wrong?